(NASDAQ: CMMB) Chemomab Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 246.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.87%.
Chemomab Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CMMB's revenue for 2029 to be $8,946,142,103, with the lowest CMMB revenue forecast at $8,946,142,103, and the highest CMMB revenue forecast at $8,946,142,103.
In 2030, CMMB is forecast to generate $43,429,556,789 in revenue, with the lowest revenue forecast at $43,429,556,789 and the highest revenue forecast at $43,429,556,789.